Anabel Salazar

【A Systematic Review of Cannabidiol Effects in Coronary Syndromes: Challenges to Clinical Translation】 Full article: https://lnkd.in/eeaj5dBb (Authored by Mario E. Zuñiga-Ayala, et al., from Hospital Regional Primero de Octubre (Mexico), etc.) #Cannabidiol (CBD), a non-psychoactive compound of #cannabis, represents a therapeutic strategy for medical conditions such as cancer, epilepsy and multiple sclerosis, and has been recently proposed as an immudomodulatory and cardioprotective drug. This work performs a systematic review of the effects of CBD in the management of #coronary_syndromes (CS), aiming to clarify and summarize the clinical and preclinical evidence of potential benefit of the use of CBD in coronary syndromes. #Myocardial_Infarction 

1

🌟 Improving pediatric health through early detection: Sickle Cell Disease screening in Catalunya According to Dr. Pablo Velasco, “The findings support neonatal screening programs, even in countries without it, as they likely decrease morbidity and could lower long-term healthcare costs.” From Catalonia to regions with high SCD prevalence, such as parts of Africa, this study reinforces the global importance of early detection in public health strategy. 🌍 #RecercaPediàtricaVH

5

🔍 Discover the cost-effectiveness of pharmacogenetic screening in treating Major Depressive Disorder (MDD). This approach could save costs and improve patient outcomes in the Spanish National Health System. Read more to understand the potential benefits and future implications. 🌐💡 #SyenzaNews #Pharmacogenetics #MajorDepression #CostEffectiveness #HealthcareInnovation https://lnkd.in/dgcPfFJc

5

2 comentarios

Qué es la #gingivitis y la #periodontitis. This educational video walks you and your patients through what #gumdisease is, with titles and subtitles in Spanish. #EFPerio #periodontology #journeytoahealthysmile https://lnkd.in/djdUXCc8

4

New article in Drugs in Context Evaluation of the criteria for renewal of LHRH agonists in patients with prostate cancer: results of the ANAREN Study Jesús Calleja-Escudero, Víctor Barrondo, Andres Rodriguez Alonso, Francisco Gómez-Veiga, Joan Bestard, Antonio Gomez Caamaño, Anne-Sophie Grandoulier, Maria Pérez-Sampietro, Venancio Chantada Abal, Raúl Poza de Celis, on behalf of ANAREN Study Group Study to determine the patterns of prescription and compliance as well as quality of life changes in patients prescribed luteinizing hormone-releasing hormone agonists. #drugsincontext #prostatecancer #LHRHagonists #oncology https://lnkd.in/dmkGpDhm

2

🎙Dr Rosa Maria Daurelio, gynaecologist specialised in reproductive medicine at Instituto Bernabeu Madrid, was one of the guest voices in a series of nine podcasts dedicated to exploring different topics related to assisted reproduction in which nine experts were able to offer their point of view. In this case, the topic was implantation failure.   These podcasts, organised by the Sociedad Española de Fertilidad (SEF), with the support of Merck, are aimed at assisted reproduction professionals.   👉Dr Daurelio insisted on the need to provide patients with honest information about the real chances of success in each specific case based on current scientific evidence. 🔗More information in the first comment of this post.

18

1 comentario

The 12th edition of the International Symposium on ATP1A3 in Disease will be held next week, November 14-15, in Barcelona, co-hosted by the Department of Pediatric Neurology, Hospital San Juan de Deu, and by the Spanish Patient Association A.E.S.H.A. As with all past editions, this Symposium will be a strategic opportunity for the scientific, medical and patient community to share information about their current studies and initiatives, ideas for new projects and collaborations to further progress in the development of an effective treatment for AHC and all ATP1A3-related syndromes and of a better healthcare for all patients worldwide. Results from three main IAHCRC Studies will be presented by their respective leaders: the OBSERV-AHC Study on the natural history of AHC by Prof. Mohamad Mikati, Duke University, USA; the QTc-AHC Study on cardiac disturbances associated to the ATP1A3-related syndromes, by Dr. Andrew Landstrom, Duke University, USA; the EEG-AHC Study on sleep in AHC, that also includes a survey for families on the quality of sleep in their children, by Dr. Simona Balestrini, University College of London, UK. Prof. Alexis Arzimanoglou, IAHCRC Past Coordinator and current Coordinator of ERN EpiCARE - Rare and Complex Epilepsies, will present the European Reference Networks (ERN's) as an essential asset at the service of rare and complex diseases such as AHC and all ATP1A3-related syndromes. In the evening of the first day of the Symposium, a brainstorming session will take place, reserved to the IAHCRC members, to discuss about the continuity of the Consortium and its future actions as an international research network. We heartily thank A.E.S.H.A. for their support in organizing this session. For more information about the Symposium, visit the official website www.atp1a3barcelona.org #IahcrcConsortium #IahcrcStudy #ObservAhcStudy #EegAhcStudy #QtcAhcStudy #IahcrcCloudPlatform  #AhcAwareness #AhcRareDisease #Atp1A3RareDiseases #RareDiseases

5

Rafael De la Espriella, cardiologist and expert in heart failure at the Hospital Clínico Universitario de Valencia, was the fifth speaker at our #BIOTOOL-CHF workshop titled "𝐓𝐚𝐜𝐤𝐥𝐢𝐧𝐠 𝐂𝐨𝐧𝐠𝐞𝐬𝐭𝐢𝐨𝐧 𝐢𝐧 𝐂𝐡𝐫𝐨𝐧𝐢𝐜 𝐇𝐞𝐚𝐫𝐭 𝐅𝐚𝐢𝐥𝐮𝐫𝐞: 𝐀 𝐌𝐮𝐥𝐭𝐢𝐬𝐭𝐚𝐤𝐞𝐡𝐨𝐥𝐝𝐞𝐫 𝐖𝐨𝐫𝐤𝐬𝐡𝐨𝐩 𝐭𝐨 𝐃𝐞𝐟𝐢𝐧𝐞 𝐚 𝐍𝐞𝐰 𝐏𝐚𝐭𝐡𝐰𝐚𝐲 𝐟𝐨𝐫 𝐈𝐦𝐩𝐫𝐨𝐯𝐢𝐧𝐠 𝐏𝐚𝐭𝐢𝐞𝐧𝐭𝐬' 𝐎𝐮𝐭𝐜𝐨𝐦𝐞𝐬." Dr. Espriella presented an impressive update on the availability and current knowledge of biomarkers and heart failure treatment. 🗣️ In his words: "𝐶𝑜𝑛𝑔𝑒𝑠𝑡𝑖𝑜𝑛 𝑖𝑠 𝑎 𝑟𝑒𝑎𝑙𝑙𝑦 𝑑𝑖𝑓𝑓𝑖𝑐𝑢𝑙𝑡 𝑎𝑛𝑑 𝑑𝑎𝑛𝑔𝑒𝑟𝑜𝑢𝑠 𝑝𝑎𝑟𝑡 𝑜𝑓 𝑡ℎ𝑒 𝑑𝑖𝑠𝑒𝑎𝑠𝑒. 𝑊𝑒 ℎ𝑎𝑣𝑒 𝑠𝑒𝑣𝑒𝑟𝑎𝑙 𝑏𝑖𝑜𝑚𝑎𝑟𝑘𝑒𝑟𝑠 𝑡𝑜 𝑚𝑜𝑛𝑖𝑡𝑜𝑟, 𝑏𝑢𝑡 𝑤𝑒 𝑛𝑒𝑒𝑑 𝑘𝑛𝑜𝑤𝑙𝑒𝑑𝑔𝑒-𝑏𝑎𝑠𝑒𝑑 𝑡𝑜𝑜𝑙𝑠 𝑡ℎ𝑎𝑡 𝑎𝑙𝑙𝑜𝑤 𝑢𝑠 𝑡𝑜 𝑢𝑠𝑒 𝑡ℎ𝑒𝑚 𝑖𝑛 𝑡ℎ𝑒 𝑚𝑜𝑠𝑡 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡 𝑤𝑎𝑦 𝑡𝑜 𝑔𝑢𝑖𝑑𝑒 𝑝𝑒𝑟𝑠𝑜𝑛𝑎𝑙𝑖𝑧𝑒𝑑 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡𝑠." This is precisely what BIOTOOL-CHF is developing: a biomarker-based diagnostic toolkit to personalize pharmacological approaches in congestive heart failure. 📸 Pictures below. Find out more about BIOTOOL-CHF 👉 https://lnkd.in/dqxg_Nz4 #BIOTOOL #EUHorizon

12

#callforreading 🎯 #review Receive alerts about the newly released paper on Targets MDPI! 🤩 Title: "Positive Inotropic Agents in Cancer Therapy: Exploring Potential Anti-Tumor Effects" 🔗 Available link: https://lnkd.in/dHEfsUiA 🤼 Authors: Eduarda Ribeiro and Nuno Vale CINTESIS - Center for Health Technology and Services Research Universidade do Porto #cancertherapy #radiationtherapy #diagnosis #drugresistance #oncology 📰 Abstract: Cancer remains a significant global health challenge despite advancements in diagnosis and treatment. Traditional cancer therapies often face limitations such as toxicity and drug resistance. Drug repurposing has emerged as a promising strategy to overcome these challenges by identifying new therapeutic uses for existing drugs. This review explores the potential of repurposing positive inotropic agents, which are traditionally used in cardiovascular medicine, for cancer therapy. Positive inotropic agents, including cardiac glycosides, β-agonists, phosphodiesterase inhibitors, and calcium sensitizers have shown preclinical evidence of anti-tumor activity through various mechanisms, such as modulation of the intracellular signaling pathways, increasing cyclic adenosine monophosphate (cAMP) levels, the production of nitric oxide, and decreasing reactive oxygen species levels. Despite the absence of specific clinical trials in this area, these findings suggest a promising avenue for further research and development of combination therapies to improve cancer treatment outcomes. However, challenges such as elucidating specific anti-tumor mechanisms, identifying predictive biomarkers, and optimizing safety profiles need to be addressed to fully realize the therapeutic potential of positive inotropic agents in oncology.

1

#TargetingMitochondria2024 Accepted Poster Communications - Part 2. You still have time to submit your posters! SORL1 DEFICIENCY IN ALZHEIMER´S PATIENTS: IMPACT ON MITOCHONDRIA AND AUTOPHAGY Guiomar Rodríguez Periñán, Research Institute Hospital 12 de Octubre, Spain AMADORI PRODUCT, FRUCTOSELYSINE, ALTERS MITOCHONDRIAL FUNCTION AND IMPAIRS ENERGY METABOLISM IN HUMAN BETA CELL LINE 1.1B4 SHIFTING TO GLYCOLYSIS Gökhan Duruksu, Kocaeli University, Turkey M.10010T>C MITOCHONDRIAL DISEASE: A CASE REPORT WITH HYPOCALCEMIA Jacob Mohr, Mech-Sense, Aalborg University Hospital, Denmark MUTANT P53 INDUCES MITOCHONDRIAL FRAGMENTATION IN PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) Maria Poles, University of Verona, Italy IMPACT OF CHROMOSOME 18 NUMERICAL IMBALANCES ON MITOCHONDRIAL BCL-2 PROTEIN EXPRESSION IN HPV-POSITIVE CERVICAL SQUAMOUS INTRAEPITHELIAL LESIONS Nikolaos Kavantzas, National and Kapodistrian University of Athens, School of Medicine,  Greece 3D CELL CULTURE MODELS TO STUDY MITOCHONDRIAL FUNCTION IN AIRWAY DISEASES Arda Tarcan, University of Southampton, United Kingdom MITOCHONDRIAL FUNCTION AND OTHER IMPORTANT PARAMETERS OF AGEING ARE IMPROVED BY CALORIC RESTRICTION IN HUMANS Melanie Scherer, Albstadt-Sigmaringen University, Germany THE PROTEIN GLYCOSYLATION MACHINERY IN B CELLS CONTROLS MITOCHONDRIAL FUNCTION Christina Brunner, Universitätsklinikum Erlangen, Germany OXIDATIVE DRUG COMBINATION OF ARSENIC TRIOXIDE AND D-VITAMIN C INDUCES DYSFUNCTION OF MITOCHONDRIA AND CYTOTOXIC ROS PRODUCTION Agata Natasza Burska, Nazarbayev University, Kazakhstan CARDIOVASCULAR AUTONOMIC NEUROPATHY IN M.3243A>G MITOCHONDRIAL DISEASE Simone Rask Nielsen, Mech-Sense, Aalborg University Hospital, Denmark GENETIC CHANGES IN MITOCHONDRIA: A POTENTIAL MARKER OF TESTICULAR TUMOR CHEMORESISTANCE? Ing. Pavlína Kabelíková,  Biomedical Research Center of the Slovak Academy of Sciences, Slovak Republic THE STUDY OF THE IMPACT OF HYPOXIA AND EPIGENETIC MODULATION ON MECHANISMS INVOLVED IN RESISTANCE OF TESTICULAR TUMORS MSc. Danica Ivovič, PhD.,  Slovenská akadémia vied / Slovak Academy of Sciences, Biomedical Research Center, Slovak Republic METABOLIC REPROGRAMMING IN CHEMICALLY INDUCED CARDIOMYOCYTES THROUGH MITOCHONDRIAL TRANSFER EunJung Park, Sungkyunkwan University, South Korea NOVEL INTRACELLULAR FLUORIMETRIC PROBES FOR ORGANELLES WITH PHOTOINDUCED BIOACTIVITY Ivo Piantanida, Rudjer Boskovic School, Croatia 🔗 Poster Submission: https://lnkd.in/ePFTf-PA #WorldMitochondriaSociety #TargetingMitochondria #mitochondria #WMS

34

Explore #Navitian's crossing capacity in the #ClinicalCase by Dr Ignacio J Amat Santos and find out why is key to success in an antegrade approach ➡️ https://lnkd.in/dCcfMPP3 #iVascular #ClinicalCases

47

📢 We would like to showcase a cross-sectional study in NursingReports! "Assessment of Diabetic Foot Prevention by Nurses" authored by Sonia Hidalgo-Ruiz, María del Valle Ramírez Durán, Belinda Basilio, Mª del Pilar Alfageme García, Juan Fabregat-Fernández, Víctor Manuel Jiménez-Cano, Maria Zoraida Clavijo-Chamorro, Adela Gomez-Luque 👩‍⚕️This cross-sectional study of 157 nurses highlights the critical role of nursing staff in preventing diabetic foot complications, such as amputations and high mortality. The study found that: - 96.58% of nurses asked patients to remove footwear for examination; - 80.25% assessed the risk of developing diabetic foot; - and 84.07% frequently educated patients on self-care. However, only 19.11% conducted group workshops, indicating the need for improved screening, skills testing, and educational activities. 📝 Read more: https://lnkd.in/gR2nEzze #MDPI #OpenAccess #NursingReports #DiabeticFoot #Podology #NursingCare #PatientSafety #DiabetesPrevention #MedicalResearch

8

2 comentarios

📢 New Guidelines for WES procedures in prenatal diagnosis by the Spanish Society of Gynecology and Obstetrics (SEGO) and Spanish Association of Prenatal Diagnosis (AEDP). 1. Trio WES 👨‍👩‍👧 is recommended as a 1️⃣ first-tier genetic test with specific structural abnormalities such:   - 💧 Bilateral hyperechogenic, dysplastic, or polycystic kidneys   - 🦴 Skeletal dysplasia   - ♻️ Recurrent anomaly   - 🧠 Craniosynostosis   - 🚼 Fetal akinesia deformation sequence   - 🔄 Multiple anomalies involving various systems   - 🧠 Central nervous system anomalies (except single anomalies)   - 🌊 Non-isolated nuchal translucency   - 💧 Non-immune hydrops fetalis 2. Previous genetic tests (such as QF-PCR and CMA) have not identified genetic alterations 🧬. 3. Strong suspicion of recurrence based on family history, such as previous fetuses or children with structural anomalies where no prior genetic studies were available 🧑‍🤝‍🧑. Each center should decide which of the four reporting levels to adopt: 1. Level 1️⃣: Primary findings 2. Level 2️⃣: Level 1 + Incidental findings (genes with high penetrance that are associated with moderate or severe childhood-onset diseases 🧒 3. Level 3️⃣: Levels 1 and 2 + Carrier Status for recessive conditions in both parents 👨‍👩‍👧‍👦. 4. Level 4️⃣: Levels 1, 2, and 3 + Secondary findings (early and late onset medically actionable ACMG gene list 🏥 Other important considerations in the guidelines covered: 1. 🛠️ Technical considerations 2. 📊 Quality assessment 3. 🩺 Clinical considerations 4. 🔄 Reanalysis 5. 💬 Pre-test and post-test genetic counselling 6. 🗄️ Data storage and data protection policies 📄 Excellent document enhancing the prenatal diagnostic landscape in Spain. https://lnkd.in/dyUjJDUp #WES #prenataldiagnostics #NGS #ultrasoundanomalies #prenatalcare #exome #SEGO Asociación Española de Diagnóstico Prenatal Fundación iMaterna #genomicmedicine

53

1 comentario

The NEOpredict-Lung study represents an importantevolution in the treatment of resectable NSCLC - Iván R González OncoAlert Lung Cancer Foundation of America Nina Maouelainin, DO, FCCP, MBA Nirmal Raut #Cancer #OncologyCenter #Hospital #NSCLC #OncoDaily #Oncology #ImmunePathways

20